This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir,
and molnupiravir in adult patients with mild-to-moderate COVID-19. This retrospective cohort …

Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19
in China due to their earlier approval by the National Medical Products Administration …

Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment
of COVID-19 in China, however, limited real-world data exists regarding their effectiveness …

Purpose To compare the effectiveness of azvudine and nirmatrelvir/ritonavir for the treatment
of coronavirus disease (COVID-19). Patients and Methods We conducted a retrospective …

Chinese guidelines prioritize the use of Azvudine and nirmatrelvir–ritonavir in COVID‐19
patients. Nevertheless, the real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir …

Background and aim Two oral antivirals (Nirmatrelvir-ritonavir and Azvudine) are widely
used in China practice during the Omicron wave of the pandemic. However, little evidence …

Background Azvudine has clinical benefits and acceptable safety against COVID-19,
including in patients with comorbidities, but there is a lack of available data for its use in …

To examine the effectiveness of azvudine and nirmatrelvir–ritonavir in treating hospitalized
patients with moderate‐to‐severe COVID‐19. We emulated a target trial with a multicenter …

Background Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …

Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …